Novo Nordisk A/S (NVO) · Earnings Release

Merck and Co Inc (MRK) · Earnings Release

Merck & Co. is expected to release its Q1 2026 earnings results on or around April 30, 2026, before the market opens. High impact expected as earnings releases often drive price movements exceeding 10%, scheduled.

4/30/2026, 12:00:00 AM

Novartis AG (NVS) · Earnings Release

First quarter 2026 results scheduled for 2026-04-28; high impact expected as a major financial update.

4/28/2026, 12:00:00 AM

Merck and Co Inc (MRK) · Other

The FDA has set a PDUFA target action date of April 28, 2026, for its review of the New Drug Application for doravirine/islatravir, an investigational HIV treatment. Approval typically impacts price by 5-10%, scheduled.

4/28/2026, 12:00:00 AM

Abbott Laboratories (ABT) · Other

Quarterly dividend with an ex-dividend date of April 15, 2026, is scheduled.

4/15/2026, 12:00:00 AM

DICK'S Sporting Goods Inc (DKS) · Other

Quarterly dividend of $1.25 per share, announced on March 11, 2026, with an ex-dividend date of March 27, 2026. This represented a 3.1% increase from the prior dividend.

3/27/2026, 12:00:00 AM

Novo Nordisk A/S (NVO) · Other

Initiated a Phase 1 clinical trial for LX9851 on March 23, 2026, a new oral, non-incretin obesity drug candidate licensed from Lexicon Pharmaceuticals.

3/23/2026, 12:00:00 AM